Pomerantz LLP is investigating claims on behalf of investors of  Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

This comes at a challenging time for gene therapies, as multiple serious AEs and fatalities have been recently reported.

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...

Robotic therapy animals could open new doors for trauma recovery, autism support, and mental health care at scale.

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

A New Jersey biotech company has paused a gene therapy trial after a participant had an unexpected adverse event and later died from a sudden, severe infection.  Rocket Pharmaceuticals said the ...

Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon ...

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease: Cranbury, New Jersey Wednesday, May 28, 2025, 14:00 Hrs [IST] Rocket P ...

CRANBURY, NJ, USA I May 27, 2025 I Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated ...